Home Cart Sign in  
Chemical Structure| 117976-89-3 Chemical Structure| 117976-89-3

Structure of Rabeprazole
CAS No.: 117976-89-3

Chemical Structure| 117976-89-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rabeprazole, an antiulcer drug, can irreversibly inhibit gastric H+/K+ ATPase pump with IC50 of 72 nM.

Synonyms: LY307640

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rabeprazole

CAS No. :117976-89-3
Formula : C18H21N3O3S
M.W : 359.44
SMILES Code : COCCCOC1=C(C)C(CS(=O)C2=NC3=C(N2)C=CC=C3)=NC=C1
Synonyms :
LY307640
MDL No. :MFCD00868879
InChI Key :YREYEVIYCVEVJK-UHFFFAOYSA-N
Pubchem ID :5029

Safety of Rabeprazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Proton Pump

In Vitro:

Cell Line
Concentration Treated Time Description References
Human lung microvascular endothelial cells (HLMVECs) 20 μM 18 hours Rabeprazole induced HIF1A mRNA expression in a dose-dependent manner PMC9105578
Dematiaceous fungi 2-128 mg/ml 72h Rabeprazole alone exhibited limited antifungal effect against all tested species. However, the median MICs of azoles and RAB in the combination revealed up to 7.7-fold and 128-fold reduction compared to that when tested alone, respectively. PMC10831725
Candida spp. 2-128 mg/ml 24h Rabeprazole alone exhibited limited antifungal effect against all tested species. However, the median MICs of azoles and RAB in the combination revealed up to 7.7-fold and 128-fold reduction compared to that when tested alone, respectively. PMC10831725
Aspergillus fumigatus 2-128 mg/ml 48h Rabeprazole alone exhibited limited antifungal effect against all tested species. However, the median MICs of azoles and RAB in the combination revealed up to 7.7-fold and 128-fold reduction compared to that when tested alone, respectively. PMC10831725
Trypanosoma cruzi epimastigotes 1 mM 4 hours To evaluate the effect of Rabeprazole on cell viability and TIM enzyme activity with different numbers of parasites in a short time. Results showed that Rabeprazole significantly reduced cell viability and TIM enzyme activity. PMC10351538
Trypanosoma cruzi epimastigotes 250 μM 24 hours To evaluate the effect of Rabeprazole on cell viability and TIM enzyme activity with different numbers of parasites in a short time. Results showed that Rabeprazole significantly reduced cell viability and TIM enzyme activity. PMC10351538
Trypanosoma cruzi epimastigotes 100–2000 μM 4 hours To evaluate the effect of Rabeprazole on cell viability and TIM enzyme activity with different numbers of parasites in a short time. Results showed that Rabeprazole significantly reduced cell viability and TIM enzyme activity. PMC10351538
Human lung microvascular endothelial cells (HLMVECs) 20 μM 18 hours Rabeprazole induced HIF1A mRNA expression in a dose-dependent manner PMC9105578
HEK293 cells 100 μM 48 hours Evaluate the effect of SR9009 on a luciferase reporter driven by the Bmal1 promoter PMC11578692
AGS cells 100 μM 48 hours To study the effect of NAM on LONP1 expression. Results showed that NAM treatment increased the expression and acetylation level of LONP1. PMC11578692
BGC823 cells 100 μM 48 hours Rabeprazole inhibited CREB phosphorylation and nuclear translocation, reducing the binding of CREB to the GPX4 promoter, thereby decreasing GPX4 expression and inducing ferroptosis. PMC11578692
Campylobacter jejuni and C. coli 16 µg/ml immediately RPZ-TH and PPIs also inhibited the motility of C. jejuni and C. coli, but had no effect on other bacteria such as V. cholerae and S. enterica. PMC101604
Helicobacter pylori 16 µg/ml immediately Rabeprazole (RPZ) and its thioether derivative (RPZ-TH) markedly inhibited the motility of H. pylori. RPZ-TH completely blocked motility at 1 µg/ml, while RPZ had an IC50 of 16 µg/ml. PMC101604

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
B10.RIII mice Experimental autoimmune uveitis (EAU) model Intraperitoneal injection 60 mg/kg/day Once daily for 7 days (from Day 7 to Day 14) To evaluate the effect of rabeprazole on the EAU mouse model. Results showed that rabeprazole reduced anterior chamber inflammation and retinal inflammation, inhibited TNF and IL-1β expression, and promoted IL-10 expression. PMC9253297
C57BL/6 mice DNBS and DSS-induced colitis models Oral 30 mg/kg Twice daily, throughout the experiment Rabeprazole failed to demonstrate any anti-colitic effect PMC9174989
Mice Endotoxemia-induced inflammatory lung injury model Oral 18 mg/kg Administered at 4 and 20 hours post-LPS Rabeprazole promotes vascular repair and resolution of inflammatory lung injury through HIF-1α/FoxM1 signaling PMC9105578
Wistar rats Anesthetized rat model Intravenous injection 4 mg/kg Single dose, lasting 2 hours To investigate the effects of Rabeprazole on the concentration of amoxicillin in gastric juice and gastric mucosa. Results showed that Rabeprazole increased the amoxicillin concentration in gastric juice but did not significantly alter its concentration in blood or gastric mucosa. PMC4007658
Mice Endotoxemia-induced inflammatory lung injury model Oral 18 mg/kg Administered at 4 and 20 hours post-LPS Rabeprazole promoted vascular repair and resolution of inflammatory lung injury through HIF-1α/FoxM1 signaling PMC9105578
Female Swiss albino mice Osteoporosis model Oral 10 mg/kg every 48 hours Every 48 hours for 18 weeks To investigate the impact of rabeprazole on osteoporosis and explore the modulatory effects of dietary calcium or alendronate on this side effect. Results showed that rabeprazole significantly reduced bone mineral density, increased trabecular separation and osteoclast number. Calcium supplementation or alendronate partially restored bone density and reduced osteoclast activity. PMC7237708

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01408186 Upper Gastrointestinal Bleedin... More >>g Less << Phase 3 Completed - Hong Kong ... More >> Prince of Wales Hospital Hong Kong, Hong Kong Japan Second Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan Izumo, Japan Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan Kyoto, Japan Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan (Satellite hospital of Osaka City University) Osaka, Japan Department of Gastroenterology, Osaka City University Graduate School of Medicine Osaka, Japan Department of Gastroenterology, Takarazuka Municipal Hospital, Hyogo, Japan (Satellite hospital of Osaka City University) Osaka, Japan Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan Osaka, Japan Department of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan Saga, Japan Less <<
NCT03658733 Helicobacter Pylori Infection Phase 4 Not yet recruiting October 31, 2019 China, Shandong ... More >> Xiuli Zuo Recruiting Jinan, Shandong, China Contact: Xiuli Zuo, PhD,MD    15588818685 ext 053188369277    zuoxiuli@sina.com    Sub-Investigator: Yue Li, MD          Sub-Investigator: Chaoran Ji, MD Less <<
NCT01918176 Healthy Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site South Miami, Florida, United States, 33143 Less <<
NCT00165672 - Completed - -
NCT03726099 Helicobacter Pylori Infection Phase 4 Not yet recruiting March 30, 2020 China, Shandong ... More >> Xiuli Zuo Jinan, Shandong, China Less <<
NCT01237353 Pharmacodynamic Not Applicable Completed - United States, California ... More >> University of California San Francisco San Francisco, California, United States, 94143 Less <<
NCT00165672 Non-erosive Gastroesophageal R... More >>eflux Disease Less << Phase 3 Completed - Japan ... More >> Nagoya, Aichi-Prefecture, Japan, 467-0001 Fukuoka, Fukuoka-Prefecture, Japan, 810-0001 Fukuoka, Fukuoka-Prefecture, Japan, 811-0213 Yukuhashi, Fukuoka-Prefecture, Japan, 824-0026 Hiroshima, Hiroshima-Prefecture, Japan, 734-0037 Osaka, Osaka-Prefecture, Japan, 530-0012 Osaka, Osaka-Prefecture, Japan, 545-0051 Saga, Saga-Prefecture, Japan, 849-0937 Otsu, Shiga-Prefecture, Japan, 520-2121 Izumo, Shimane-Prefecture, Japan, 693-0021 Bunkyo-ku, Tokyo, Japan, 113-0022 Shinjuku-ku, Tokyo, Japan, 162-0052 Ube, Yamaguchi-Prefecture, Japan, 755-0046 Less <<
NCT01237353 - Completed - -
NCT00234117 Bronchial Asthma|Gastroesophag... More >>eal Reflux Less << COMPLETED - Ponce Gastroentrology Research... More >>, Ponce, 00717, Puerto Rico Less <<
NCT01772290 Healthy Volunteer Phase 1 Completed - United States, Florida ... More >> Daytona Beach, Florida, United States, 32117 United States, Texas Dallas, Texas, United States, 75247 Less <<
NCT01249651 - Completed - -
NCT03530995 Drug Drug Interaction ... More >> Autoimmune Diseases Fibrotic Disease Less << Phase 1 Recruiting June 15, 2019 United Kingdom ... More >> Quotient Sciences Ltd Recruiting Ruddington, Nottingham, United Kingdom, NG11 6JS Contact: Nand Singh, MD Less <<
NCT01249651 Heartburn Phase 4 Completed - China ... More >> Research Site Bejing, China Less <<
NCT00747695 GERD Phase 1 Completed - -
NCT01264822 - Completed - Japan ... More >> Nagoya, Aichi, Japan Hirosaki, Aomori, Japan Kashiwa, Chiba, Japan Matsuyama, Ehime, Japan Fukuyama, Hiroshima, Japan Sapporo, Hokkaido, Japan Amagasaki-shi, Hyogo, Japan Kobe, Hyogo, Japan Hitachi, Ibaraki, Japan Takamatsu, Kagawa, Japan Isehara, Kanagawa, Japan Sendai, Miyagi, Japan Nagano-shi, Nagano, Japan Suzaka, Nagano, Japan Oita-shi, Oita, Japan Yufu, Oita, Japan Kurashiki, Okayama, Japan Tsuyama, Okayama, Japan Hirakata, Osaka, Japan Osakasayama, Osaka, Japan Takatsuki, Osaka, Japan Matsue, Shimane, Japan Hamamatsu, Shizuoka, Japan Otawara-shi, Tochigi, Japan Chuo, Tokyo, Japan Itabashi, Tokyo, Japan Minato-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Yamagata-shi, Yamagata, Japan Ube, Yamaguchi, Japan Fukuoka, Japan Hiroshima, Japan Kyoto, Japan Nagasaki, Japan Nara, Japan Niigata, Japan Okayama, Japan Osaka, Japan Saga, Japan Tottori, Japan Toyama, Japan Yamaguchi, Japan Less <<
NCT00287391 Insomnia|GERD PHASE4 COMPLETED 2025-12-06 UNC Gastroenterology and UNC S... More >>leep Disorders Center, Chapel Hill, North Carolina, 27599, United States Less <<
NCT00539240 Gastroesophageal Reflux Diseas... More >>e Less << Phase 2 Phase 3 Completed - United States, Arizona ... More >> Southern Arizona VA Health Care System, Tucson Tucson, Arizona, United States, 85723 Less <<
NCT00354757 GERD Phase 4 Completed - Taiwan ... More >> National Taiwan Univeristy Hospital Taipei, Taiwan, 100 Less <<
NCT00539240 - Completed - -
NCT01397084 Gastroesophageal Reflux Diseas... More >>e GERD Reflux Esophagitis Less << Phase 4 Completed - -
NCT01397084 - Completed - -
NCT02463643 Esophagitis, Reflux Phase 2 Completed - Japan ... More >> Tokyo, Japan Less <<
NCT02509923 Healthy Phase 1 Completed - Japan ... More >> Tokyo, Japan Less <<
NCT01153659 Healthy Phase 1 Completed - United States, Oklahoma ... More >> Oklahoma Foundation for Digestive Research Oklahoma City, Oklahoma, United States, 73104 Less <<
NCT02311946 Healthy Phase 1 Completed - United States, Florida ... More >> MRA Clinical Research - Phase 1 Miami, Florida, United States, 33143 Miami Research Associates, LLC South Miami, Florida, United States, 33143 MRA Clinical Research, LLC South Miami, Florida, United States, 33143 Less <<
NCT02847455 Duodenal Ulcer Phase 2 Phase 3 Completed - -
NCT00681005 GERD Not Applicable Completed - -
NCT01287091 Healthy Volunteer Phase 1 Completed - United States, Texas ... More >> Investigational Site Austin, Texas, United States, 78744 Less <<
NCT00214552 Asthma Gastro... More >>esophageal Reflux Disease Less << Phase 3 Completed - United States, Washington ... More >> ASTHMA, Inc. Richland, Washington, United States, 99352 ASTHMA, Inc. Seattle, Washington, United States, 98105 Less <<
NCT00125736 Stomach Ulcer Phase 4 Completed - Japan ... More >> Kariya, Aichi, Japan Nagoya, Aichi, Japan Seto, Aichi, Japan Toyoake, Aichi, Japan Toyohashi, Aichi, Japan Akita, Akira, Japan Urayasu, Chiba, Japan Niihama, Ehime, Japan Chikushino, Fukoka, Japan Kurume, Fukoka, Japan Oumuta, Fukoka, Japan Tagawa, Fukoka, Japan Sabae, Fukui, Japan Hashima, Gifu, Japan Asahikawa, Hokkaido, Japan Sapporo, Hokkaido, Japan Miki, Hyogo, Japan Kanazawa, Ishikawa, Japan Kumamotoi, Kumamoto, Japan Sendai, Miyagi-prefecture, Japan Kashihara, Nara, Japan Yufu, Oita, Japan Ikeda, Osaka, Japan Izumisano, Osaka, Japan Kadoma, Osaka, Japan Takatsuki, Osaka, Japan Hasuda, Saitama, Japan Kitaadachi-gun, Saitama, Japan Matue, Shimane, Japan Hamamatsu, Shizouka, Japan Minato-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Shinjyuku-ku, Tokyo, Japan Shimonoseki, Yamaguchi, Japan Fukoka, Japan Gifu, Japan Hiroshima, Japan Kouchi, Japan Kyoto, Japan Nara, Japan Nigata, Japan Oita, Japan Saga, Japan Less <<
NCT00304421 Gastroesophageal Reflux Diseas... More >>e Less << Phase 4 Completed - United States, California ... More >> VA Greater Los Angeles Healthcare System Los Angeles, California, United States, 90073 Less <<
NCT01089543 Functional Dyspepsia Phase 2 Completed - Japan ... More >> Nagoya, Aichi, Japan Chikushino, Fukuoka, Japan Kitakyushu, Fukuoka, Japan Maebashi, Gunma, Japan Sapporo, Hokkaido, Japan Kobe, Hyogo, Japan Nishinomiya, Hyogo, Japan Tsuchiura, Ibaraki, Japan Takamatsu, Kagawa, Japan Yokohama, Kanagawa, Japan Sendai, Miyagi, Japan Yufu, Oita, Japan Nakagami, Okinawa, Japan Hirakata, Osaka, Japan Moriguchi, Osaka, Japan Suita, Osaka, Japan Takatsuki, Osaka, Japan Karatsu, Saga, Japan Kusatsu, Shiga, Japan Izumo, Shimane, Japan Fujieda, Shizuoka, Japan Hamamatsu, Shizuoka, Japan Otawara, Tochigi, Japan Shimotsuga, Tochigi, Japan Bunkyo, Tokyo, Japan Mitaka, Tokyo, Japan Nakano, Tokyo, Japan Ota, Tokyo, Japan Setagaya, Tokyo, Japan Shibuya, Tokyo, Japan Shinagawa, Tokyo, Japan Akita, Japan Fukuoka, Japan Gifu, Japan Hiroshima, Japan Kagoshima, Japan Kochi, Japan Kumamoto, Japan Kyoto, Japan Miyazaki, Japan Oita, Japan Osaka, Japan Saga, Japan Saitama, Japan Shizuoka, Japan Yamagata, Japan Less <<
NCT01136317 Gastroesophageal Reflux Phase 2 Completed - France ... More >> CHU de Nantes Nantes, France, 44093 Less <<
NCT03521726 Helicobacter Pylori Infection Phase 4 Recruiting October 26, 2019 Taiwan ... More >> Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Recruiting Taipei, Taiwan, 10449 Contact: Tai-cherng Liou, MD    886-2-25433535 ext 3990    mmhltc@gmail.com Less <<
NCT01513785 Functional Dyspepsia Phase 2 Completed - China, Shanghai ... More >> GI Division, Shanghai Jiao-Tong University School of Medicine Renji Hospital Shanghai, Shanghai, China, 200001 Less <<
NCT01089543 - Completed - -
NCT00464308 - Completed - -
NCT00511745 - Terminated(Due to the achievem... More >>ent of minimum required sample size and new changes in local regulations.) Less << - -
NCT02037477 - Completed - -
NCT02037477 Healthy Volunteers Phase 3 Completed - Japan ... More >> Fukuoka-shi, Fukuoka, Japan Less <<
NCT03220191 Healthy Volunteer Phase 1 Completed - United States, Connecticut ... More >> Pfizer New Haven Clinical Research Unit New Haven, Connecticut, United States, 06511 Less <<
NCT00378287 GERD Phase 1 Completed - -
NCT02638584 Gastric Cancer Phase 4 Unknown October 2017 Korea, Republic of ... More >> HALLYM UNIVERSITY MEDICAL CENTER, Chuncheon Sacred Heart Hospital Recruiting Chuncheon, Gangwon-do, Korea, Republic of Contact: ChangSeok Bang, MD,PhD       cloudslove@hallym.or.kr Less <<
NCT00236392 Gastroesophageal Reflux ... More >> Heartburn Less << Phase 3 Completed - -
NCT00132496 Gastroesophageal Reflux Diseas... More >>e Less << Phase 2 Completed - -
NCT01990378 Healthy Phase 1 Completed - India ... More >> AXIS Clinicals Limited Miyapur, Hyderabad, India, 500 050 Less <<
NCT00464308 Gastro-oesophageal Reflux Phase 4 Completed - Australia ... More >> Belconnen, Australia Bondi Junction, Australia Brookvale, Australia Browns Plains, Australia Campbelltown, Australia Campsie, Australia Caringbah, Australia Castle Hill, Australia Charlestown, Australia Dapto, Australia Darlinghurst, Australia Dubbo, Australia Elizabeth, Australia Fairfield, Australia Hoppers Crossing, Australia Ingleburn, Australia Leichhardt, Australia Maroubra, Australia Melton, Australia Mount Druitt, Australia Oaklands Park, Australia Royal Park, Australia Sydney, Australia Wentworthville, Australia Wyoming, Australia Less <<
NCT01990586 Healthy Phase 1 Completed - India ... More >> AXIS Clinicals Limited Miyapur, Hyderabad, India, 500 050 Less <<
NCT00237367 Gastroesophageal Reflux Phase 4 Completed - -
NCT00216450 Helicobacter Infections ... More >> Bacterial Infections Less << Phase 4 Completed - -
NCT00132496 - Completed - -
NCT00517114 Gastroesophageal Reflux ... More >> Laryngitis Less << Not Applicable Completed - China ... More >> Queen Mary Hospital Hong Kong, China Less <<
NCT01566643 Helicobacter Pylori Infection Phase 4 Unknown December 2012 Taiwan ... More >> Buddhist Tzu Chi General Hospital Recruiting Hualien, Taiwan, 97002 Contact: Ming-Cheh CHEN, MD    +886-910-521003    MingCheh_chen@tzuchi.com.tw    Principal Investigator: Ming-Cheh CHEN, MD          Sub-Investigator: Chi-Tan HU, PhD, MD          Sub-Investigator: Wei-Yi RAY, MD Less <<
NCT02423187 - Completed - Japan ... More >> Nagoya, Japan Osaka, Japan Tokyo, Japan Less <<
NCT00216489 Gastroesophageal Reflux ... More >> Heartburn Less << Phase 4 Completed - -
NCT00648349 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT02569554 Healthy Phase 1 Completed - Belgium ... More >> Pfizer Clinical Research Unit Brussels, Belgium, B-1070 Less <<
NCT01954043 Cancer Phase 1 Completed - United States, Arizona ... More >> GSK Investigational Site Goodyear, Arizona, United States, 85338 United States, Texas GSK Investigational Site Dallas, Texas, United States, 75201 United States, Washington GSK Investigational Site Tacoma, Washington, United States, 98405 Australia, Victoria GSK Investigational Site Heidelberg, Victoria, Australia, 3084 GSK Investigational Site Melbourne, Victoria, Australia, 3004 United Kingdom GSK Investigational Site London, United Kingdom, W1G 6AD Less <<
NCT00649493 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT00649194 Healthy Phase 1 Completed - United States, North Dakota ... More >> PRACS Institute, Ltd. Fargo, North Dakota, United States, 58104 Less <<
NCT01286194 - Completed - -
NCT01202071 Healthy Phase 2 Completed - Japan ... More >> Toshima-ku, Tokyo, Japan Less <<
NCT00614536 - Completed - -
NCT01202071 - Completed - -
NCT00838526 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << Phase 3 Completed - United States, Illinois ... More >> Ltd. Moline, Illinois, United States, 61265 Midwest Clinical Moline, Illinois, United States, 61265 Research Associates Moline, Illinois, United States, 61265 Moline, Illinois, United States, 61265 Less <<
NCT00839306 - Completed - -
NCT01186497 Healthy Phase 1 Completed - -
NCT00220857 Normal Subjects PHASE4 COMPLETED 2025-09-07 Temple University School of Me... More >>dicine, Philadelphia, Pennsylvania, 19140, United States Less <<
NCT02699710 Healthy Volunteer Phase 1 Completed - United Kingdom ... More >> Quotient Clinical Ltd, Clinical Research Unit Nottingham, United Kingdom, NG11 6JS Less <<
NCT00839306 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << Phase 3 Completed - United States, Illinois ... More >> Associates, Ltd. Moline, Illinois, United States, 61265 Midwest Clinical Moline, Illinois, United States, 61265 Research Moline, Illinois, United States, 61265 Moline, Illinois, United States, 61265 Less <<
NCT00992589 Gastroesophageal Reflux Phase 3 Completed - -
NCT00992589 - Completed - -
NCT02477306 Healthy Phase 1 Completed - Egypt ... More >> Genuine Research Center GRC Cairo, Egypt Less <<
NCT00838526 - Completed - -
NCT03037606 Gastroesophageal Reflux Diseas... More >>e Less << Phase 4 Completed - Turkey ... More >> Ege University Facult of Medicine Gastroenterology Department Izmir, Turkey, 35100 Less <<
NCT02446483 - Completed - -
NCT01277718 Healthy Volunteer Phase 1 Completed - -
NCT03658473 Gastric Lesion Phase 3 Completed - Brazil ... More >> Galeno Desenvolvimento de Pesquisas Clinicas Ltda. Campinas, SP, Brazil, 13087-010 Less <<
NCT01277718 - Completed - -
NCT00658528 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << Phase 3 Completed - -
NCT00658775 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << Phase 3 Completed - -
NCT00658775 - Completed - -
NCT01575899 Helicobacter Pylori Infection Phase 4 Terminated(Early termination d... More >>ue to efficacy) Less << - Taiwan ... More >> Buddhist Tzu Chi General Hospital Hualien, Taiwan, 97002 Less <<
NCT00658632 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << Phase 3 Completed - -
NCT00658632 - Completed - -
NCT01037491 Gastric Ulcer ... More >> Duodenal Ulcer Less << Not Applicable Unknown December 2010 Taiwan ... More >> Taipei Veterans General Hospital Recruiting Taipei, Taiwan, 11217 Contact: Jiing-Chyuan Luo, M.D.    886-2-28712121 ext 3346    jcluo@vghtpe.gov.tw    Principal Investigator: Jiing-Chyuan Luo, M.D. Less <<
NCT01241409 Healthy Phase 1 Completed - -
NCT01575899 - Terminated(Early termination d... More >>ue to efficacy) Less << - -
NCT01699113 Hypergastrinaemia Phase 1 Completed - United Kingdom ... More >> Hammersmith Medicines Research London, United Kingdom Less <<
NCT00553449 Gastroesophageal Reflux ... More >> Heartburn Less << Phase 3 Completed - -
NCT00222170 Esophageal Reflux PHASE2 COMPLETED 2025-05-07 University of Kansas Medical C... More >>enter, Kansas City, Kansas, 66160, United States Less <<
NCT02446483 Gastrointestinal Diseases Phase 4 Completed - Egypt ... More >> GSK Investigational Site Cairo, Egypt Less <<
NCT02475161 Healthy Phase 1 Completed - United States, Kansas ... More >> Overland Park, Kansas, United States Less <<
NCT00165841 - Completed - -
NCT00658528 - Completed - -
NCT00165841 Gastroesophageal Reflux Diseas... More >>e Less << Phase 2 Completed - United States, California ... More >> Quality Care Medical Center Inc. Vista, California, United States, 92085 Less <<
NCT00747526 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << Phase 1 Completed - United States, Arkansas ... More >> Little Rock, Arkansas, United States United States, California Oakland, California, United States United States, District of Columbia Washington, District of Columbia, United States United States, Florida Maitland, Florida, United States United States, Kentucky Louisville, Kentucky, United States United States, Mississippi Jackson, Mississippi, United States United States, Missouri Bridgeton, Missouri, United States United States, New Jersey Long Branch, New Jersey, United States United States, North Carolina Greenville, North Carolina, United States United States, Ohio Cleveland, Ohio, United States Toledo, Ohio, United States Youngstown, Ohio, United States United States, Texas Houston, Texas, United States Belgium Antwerpen, Belgium Brussel, Belgium Brazil Sao Paulo, Brazil Poland Lublin, Poland Warszawa, Poland United Kingdom Barnsley N/A, United Kingdom London, United Kingdom Less <<
NCT00787891 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << Phase 3 Completed - -
NCT00787891 - Completed - -
NCT01219764 Helicobacter Infections Phase 4 Completed - Lebanon ... More >> American University of Beirut - Medical Center Beirut, Lebanon Less <<
NCT00989300 Healthy Phase 1 Completed - -
NCT00911534 - Completed - -
NCT00236197 - Completed - -
NCT03108287 Helicobacter Pylori Infection Phase 4 Completed - -
NCT01008696 Reflux Esophagitis Phase 4 Completed - -
NCT00236184 Heartburn Phase 3 Completed - United States, California ... More >> Jeffrey L. Newman Vista, California, United States, 92084 Less <<
NCT00911534 Symptomatic Gastroesophageal R... More >>eflux Disease (sGERD) Less << Phase 3 Completed - -
NCT01008696 - Completed - -
NCT00236197 Heartburn Phase 3 Completed - United States, New York ... More >> New York Center For Clinical Research Lake Success, New York, United States, 11042 Less <<
NCT00855361 Gastroesophageal Reflux Phase 1 Completed - United States, California ... More >> Orange, California, United States United States, District of Columbia Washington, District of Columbia, United States United States, Georgia Augusta, Georgia, United States United States, Illinois Maywood, Illinois, United States United States, Kentucky Louisville, Kentucky, United States United States, Louisiana Shreveport, Louisiana, United States United States, Michigan Lansing, Michigan, United States United States, Nebraska Omaha, Nebraska, United States United States, New York Brooklyn, New York, United States United States, Ohio Toledo, Ohio, United States Germany Aachen, Germany Poland Bydgoszcz, Poland Lublin Poland, Poland Odz, Poland Poznan N/A, Poland United Kingdom Barnsley N/A, United Kingdom Manchester, United Kingdom Preston, United Kingdom Sheffield, United Kingdom Less <<
NCT01101646 Gastroesophageal Reflux Phase 1 Completed - United States, Kansas ... More >> Overland Park, Kansas, United States Less <<
NCT01321567 - Completed - -
NCT01398410 - Completed - -
NCT03290703 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> Quotient Clinical Ltd, Clinical Research Unit Nottingham, United Kingdom, NG11 6JS Less <<
NCT01398410 Gastric Ulcers Duodenal Ulcers... More >> Caused by Low-dose Aspirin Less << Phase 2 Phase 3 Completed - -
NCT02541786 Helicobacter Pylori Infection Phase 4 Completed - Taiwan ... More >> Kaohsiung Medical University Hospital Kaohsiung, Taiwan, 807 Kaohsiung Veterans General Hospital Kaohsiung, Taiwan, 813 Less <<
NCT00838682 - Terminated(Terminated before t... More >>he complete enrollment due to slow enrollment) Less << - -
NCT01391715 Gastroesophageal Reflux Diseas... More >>e Less << Phase 3 Withdrawn(patients could not b... More >>e recuited within study duration) Less << December 2012 Korea, Republic of ... More >> Haeundae Paik Hospital, Inje University School of Medicine Busan, Korea, Republic of, 612-030 Less <<
NCT00861640 Nonvariceal Upper Gastrointest... More >>inal Bleeding Less << Phase 4 Unknown April 2010 Taiwan ... More >> Kaohsiung Medical University Hospital Recruiting Kaohsiung, Taiwan, 807 Contact: Chien-Yu Lu, MD    886-7-3121101 ext 7451    dr820188@pchome.com.tw    Principal Investigator: Chien-Yu Lu, MD Less <<
NCT00236184 - Completed - -
NCT01140828 Osteoarthritis ... More >> Arthritis, Rheumatoid Dyspepsia Less << Phase 3 Completed - China, Hong Kong ... More >> Prince of Wales Hospital Hong Kong, Hong Kong, China Less <<
NCT02767479 H. Pylori Infection Phase 3 Completed - Japan ... More >> Hamamatsu University School of Medicine Hamamatsu, Shizuoka, Japan, 431-3192 Less <<
NCT03397680 Helicobacter Pylori Infection Phase 1 Active, not recruiting May 15, 2018 Thailand ... More >> Thammasat University Hospital Khlong Luang, Patumthanee, Thailand, 12121 Less <<
NCT00844675 Early Gastric Adenocarcinoma ... More >> Adenocarcinoma, Tubular Less << Phase 4 Completed - Korea, Republic of ... More >> Catholic University, Gangnam St. Mary's Hospital Seoul, Ban-po dong 505, Korea, Republic of, 137-040 Less <<
NCT02605395 Gastrointestinal Diseases Phase 4 Completed - Egypt ... More >> GSK Investigational Site Cairo, Egypt Less <<
NCT02605395 - Completed - -
NCT00838682 Peptic Ulcer Hemorrhage Phase 4 Terminated(Terminated before t... More >>he complete enrollment due to slow enrollment) Less << - Korea, Republic of ... More >> Bucheon St. Mary's Hospital Bucheon, Kyungkido, Korea, Republic of Uijeongbu St.Mary's Hospital Uijeongbu, Kyungkido, Korea, Republic of Less <<
NCT02986685 Refractory Reflux Esophagitis Phase 4 Unknown November 2017 China, Shaanxi ... More >> Xijing Hosipital of Digestive Disease Recruiting Xi`an, Shaanxi, China, 710032 Contact: Yongquan Shi, professor    86-029-84771515    shiyquan@fmmu.edu.cn Less <<
NCT03802318 Helicobacter Pylori Infection|... More >>Helicobacter Gastritis|Helicobacter-Associated Pyloric Ulcer Less << UNKNOWN 2025-12-20 Chang-Gung memorial hospital a... More >>t Keelung, Keelung, 20401, Taiwan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.78mL

0.56mL

0.28mL

13.91mL

2.78mL

1.39mL

27.82mL

5.56mL

2.78mL

References

 

Historical Records

Categories